Deventer, 6 March 2026 – 819 Capital Partners has acquired the key assets of Lead Pharma, thereby realizing a continuation based on the company’s patent portfolio and associated research programs.
The transaction includes intellectual property rights, research data, and selected development programs.
Lead Pharma develops innovative small-molecule medicines for the treatment of cancer and autoimmune diseases. Over the past years, the company built a strong research platform and multiple drug candidates, collaborating with international pharmaceutical companies such as Roche and Sanofi.
The acquisition is realized by 819 Capital Partners, through its 819 Evergreen Fund, together with Waterman Ventures and the former management of Lead Pharma. Going forward, the focus will be on the further development and valorization of the most promising components of the portfolio of Lead Pharma.
Following a period of financial restructuring, the activities have been secured through an asset transaction. This transaction lays a new foundation for the continuation and further development of the programs, and for entering into new collaborations aimed at advancing development.
Frans van den Berg, Chief Executive Officer of Lead Pharma, commented: “This asset acquisition with the support of 819 Capital Partners enables us to continue Lead Pharma’s projects in a focused manner and to make the development of new medicines for patients possible.”
819 Capital Partners views the transaction as a strategic investment in a mature biotech patent portfolio, with the aim of advancing the development of the programs and creating value through further development and strategic partnerships.
About 819 Capital Partners
819 Capital Partners is an investment firm managing multiple funds with targeted investment strategies. Its open-ended 819 Evergreen Fund is quarterly open for new investors and invests in companies focused on deep-tech and med-tech. The firm invests in sectors such as healthcare and technology, addressing societal challenges including aging populations.
